semaglutide polycystic kidney disease GLP‐1RA Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis - Wu - 2025 - The FASEB Journal Autosomal Dominant Polycystic Kidney Disease

Co-primary end points 10 : Mean percentage change in body weight from baseline to week 64 Percentage of patients achieving 5% weight loss from baseline to week 64 Confirmatory secondary end points 10 : Percentage of patients achieving 10% weight loss from baseline to week 64 Percentage of patients achieving 15% weight loss from baseline to week 64 Percentage of patients achieving 20% weight loss from baseline to week 64 Patient Profiles Start the conversation with patients who are ready for a GLP-1 in a form that may be more familiar Didnt think he was ready for a GLP-1 for weight loss before Age: 30s-40s BMI: 30-34 kg/m Who is this patient

Mature prescribing-information safety envelope across Mounjaro and Zepbound

Provided solely for qualified laboratory and research use

It contains 0.9% benzyl alcohol as a preservative, which lets you draw from the same vial multiple times over about 28 days